

## Table of Contents

Number	Title
1	Table 00: Comments
2	Table 01: Study population and enrolment information
3	Table 02: Patients by region, country, and cohort
4	Table 03 : Demographic Characteristics
5	Table 04 : Care setting , Type of AF and Insurance
6	Table 05 : Vital signs and life style
7	Table 06 : Clinical History
8	Table 07 : Treatment for stroke prophylaxis
9	Table 08: Treatment
10	Table 09 : Risk scores
11	Table 10: Treatment at baseline by CHA2DS2-VASc score
12	Table 11: Treatment at baseline by HAS-BLED score
13	Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
14	Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
15	Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
16	Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
17	Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
18	Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
19	Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4

### Table 00: Comments

- 1 The data was extracted from the GARFIELD-AF registry database on 28 JUL 2016
- 2 The data includes retrospective patients in cohort 1 and prospective patients in cohort 1, 2, 3, 4 and 5
- 3 The variable 'Congestive heart failure' was split into 'History of CHF' and 'Current CHF' in cohorts 3, 4 and 5. History of and/or current CHF were used to identify CHF in cohort 3, 4 and 5 patients (Table 6)
- 4 The variable 'Coronary artery disease' was split into 'History of CAD' and 'Current CAD' in cohorts 3, 4 and 5. History of and/or current CAD were used to identify CAD in cohort 3, 4 and 5 patients (Table 6)
- 5 The variable 'Other thromboembolism' is not recorded for patients in cohort 3, 4 and 5
- 6 The option 'None' was added in the CRF for the 'Chronic renal disease' field in cohort 3, 4 and 5. The percentages for the variable 'Moderate to severe CKD' are estimated assuming that patients with 'unknown' stage of CKD are without 'Moderate to severe CKD' (Table 6)
- 7 Table 7 describes the baseline treatment for stroke prophylaxis. For each treatment group identifier options are mutually exclusive. The option 'unknown' includes combination of treatments
- 8 Table 8 shows the baseline treatment for stroke prophylaxis with non mutually exclusive groups
- 9 Table 12 shows INR values and TTR for patients treated with VKA±AP at baseline. INR readings during the first year of follow-up were included in the analysis. Values less than 0.8 or greater than 20 were removed since these values may not be plausible. Patients on VKA±AP at enrolment but with fewer than three readings during the follow-up were excluded from the analysis. Patient-level TTR was estimated by linear interpolation according to Rosendaal et al (1993), using 2.0-3.0 as the target INR range. TTR was estimated using INR readings until discontinuation or interruption of VKA or the end of follow-up. In addition, TTR was estimated between two consecutive INR readings only if the interval did not exceed 90 days.
- 10 Tables 13 and 14 describe events during the first year of follow-up for patients in cohorts 1-4. Only the first occurrence of each event was taken into account.
- 11 Table 13 Congestive heart failure during the follow-up includes new congestive heart failure or worsening of pre-existing congestive heart failure.

**Table 01: Study population and enrolment information  
Full Analysis Dataset : THAILAND**

Number of prospective patients (C1+C2+C3+C4+C5 )	1494
Number of enrolling sites	22
Number of enrolling countries	1
Enrolment period	27APR2012 - 23JUL2016
Duration of enrolment (months)	50.9

**Table 02: Patients by region, country, and cohort  
Full Analysis Dataset : THAILAND**

<b>Region</b>	<b>Country</b>	<b>Cohort 2 (N=190)</b>	<b>Cohort 3 (N=456)</b>	<b>Cohort 4 (N=415)</b>	<b>Cohort 5 (N=433)</b>	<b>Total Prospective patients Cohorts 1 to 5 (N=1494)</b>	<b>Total Prospective patients Cohorts 1 to 4 (N=1061)</b>
Asia	Thailand	190	456	415	433	1494	1061

**Table 03 : Demographic Characteristics  
Full Analysis Dataset : THAILAND**

Variable	Statistics	Cohort 2 (N=190) (n %)	Cohort 3 (N=456) (n %)	Cohort 4 (N=415) (n %)	Cohort 5 (N=433) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1494)	Total Prospective patients Cohorts 1 to 4 (N=1061)
Sex, n(%)	n (missing)	190 (0)	456 (0)	415 (0)	433 (0)	1494 (0)	1061 (0)
	Male	85 (44.7)	219 (48.0)	228 (54.9)	227 (52.4)	759 (50.8)	532 (50.1)
	Female	105 (55.3)	237 (52.0)	187 (45.1)	206 (47.6)	735 (49.2)	529 (49.9)
Age at Diagnosis (Years)	n (missing)	190 (0)	456 (0)	415 (0)	433 (0)	1494 (0)	1061 (0)
	Mean (SD)	67.1 (12.3)	66.2 (11.7)	67.0 (11.6)	67.3 (11.7)	66.9 (11.7)	66.7 (11.7)
	Median (IQR)	67.5 (58.0 to 76.0)	67.0 (59.0 to 74.5)	67.0 (59.0 to 76.0)	68.0 (60.0 to 76.0)	67.0 (59.0 to 75.0)	67.0 (59.0 to 75.0)
	Min to Max	33 to 92	21 to 93	23 to 97	20 to 98	20 to 98	21 to 97
Age Group, n(%)	n (missing)	190 (0)	456 (0)	415 (0)	433 (0)	1494 (0)	1061 (0)
	<65	78 (41.1)	190 (41.7)	167 (40.2)	179 (41.3)	614 (41.1)	435 (41.0)
	65-74	54 (28.4)	152 (33.3)	130 (31.3)	126 (29.1)	462 (30.9)	336 (31.7)
	>=75	58 (30.5)	114 (25.0)	118 (28.4)	128 (29.6)	418 (28.0)	290 (27.3)
Time since AF Diagnosis (Weeks)	n (missing)	127 (63)	247 (209)	161 (254)	179 (254)	714 (780)	535 (526)
	Mean (SD)	1.99 (1.66)	2.32 (1.75)	1.95 (1.52)	2.40 (1.73)	2.20 (1.69)	2.13 (1.67)
	Median (IQR)	1.70 (0.50 to 3.10)	1.80 (0.80 to 4.00)	1.70 (0.50 to 3.00)	2.00 (1.00 to 3.80)	1.80 (0.80 to 3.70)	1.80 (0.70 to 3.50)
	Min to Max	0.1 to 6.0	0.1 to 6.0	0.1 to 5.8	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0
Race, n(%)	n (missing)	190 (0)	456 (0)	415 (0)	433 (0)	1494 (0)	1061 (0)
	Caucasian	-	-	1 (0.2)	1 (0.2)	2 (0.1)	1 (0.1)
	Asian (Not Chinese)	190 (100.0)	456 (100.0)	413 (99.5)	431 (99.5)	1490 (99.7)	1059 (99.8)
	Chinese	-	-	1 (0.2)	1 (0.2)	2 (0.1)	1 (0.1)

**Table 03 : Demographic Characteristics  
Full Analysis Dataset : THAILAND**

Variable	Statistics	Cohort 2 (N=190) (n %)	Cohort 3 (N=456) (n %)	Cohort 4 (N=415) (n %)	Cohort 5 (N=433) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1494)	Total Prospective patients Cohorts 1 to 4 (N=1061)
Region, n(%)	n (missing)	190 (0)	456 (0)	415 (0)	433 (0)	1494 (0)	1061 (0)
	Asia	190 (100.0)	456 (100.0)	415 (100.0)	433 (100.0)	1494 (100.0)	1061 (100.0)

**Table 04 : Care setting , Type of AF and Insurance  
Full Analysis Dataset : THAILAND**

Variable	Statistics	Cohort 2 (N=190) (n %)	Cohort 3 (N=456) (n %)	Cohort 4 (N=415) (n %)	Cohort 5 (N=433) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1494)	Total Prospective patients Cohorts 1 to 4 (N=1061)
Care Setting Speciality at Diagnosis, n(%)	n (missing)	190 (0)	456 (0)	415 (0)	433 (0)	1494 (0)	1061 (0)
	Internal Medicine	38 (20.0)	125 (27.4)	137 (33.0)	140 (32.3)	440 (29.5)	300 (28.3)
	Cardiology	129 (67.9)	256 (56.1)	217 (52.3)	225 (52.0)	827 (55.4)	602 (56.7)
	Neurology	10 (5.3)	15 (3.3)	17 (4.1)	11 (2.5)	53 (3.5)	42 (4.0)
	Geriatrics	2 (1.1)	2 (0.4)	6 (1.4)	4 (0.9)	14 (0.9)	10 (0.9)
	Primary Care/General Practice	11 (5.8)	58 (12.7)	38 (9.2)	53 (12.2)	160 (10.7)	107 (10.1)
Care Setting Location at Diagnosis, n(%)	n (missing)	190 (0)	456 (0)	415 (0)	433 (0)	1494 (0)	1061 (0)
	Hospital	180 (94.7)	412 (90.4)	369 (88.9)	403 (93.1)	1364 (91.3)	961 (90.6)
	Office	3 (1.6)	19 (4.2)	10 (2.4)	-	32 (2.1)	32 (3.0)
	Emergency room	7 (3.7)	25 (5.5)	36 (8.7)	30 (6.9)	98 (6.6)	68 (6.4)
Type of AF Diagnosed, n(%)	n (missing)	190 (0)	456 (0)	415 (0)	433 (0)	1494 (0)	1061 (0)
	Permanent	5 (2.6)	22 (4.8)	6 (1.4)	19 (4.4)	52 (3.5)	33 (3.1)
	Persistent	40 (21.1)	114 (25.0)	90 (21.7)	93 (21.5)	337 (22.6)	244 (23.0)
	Paroxysmal	49 (25.8)	128 (28.1)	127 (30.6)	122 (28.2)	426 (28.5)	304 (28.7)
	New	96 (50.5)	192 (42.1)	192 (46.3)	199 (46.0)	679 (45.4)	480 (45.2)
Treatment Costs, n(%)	n (missing)	178 (0)	409 (0)	365 (0)	400 (0)	1352 (0)	952 (0)

**Table 04 : Care setting , Type of AF and Insurance  
Full Analysis Dataset : THAILAND**

Variable	Statistics	Cohort 2 (N=190) (n %)	Cohort 3 (N=456) (n %)	Cohort 4 (N=415) (n %)	Cohort 5 (N=433) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1494)	Total Prospective patients Cohorts 1 to 4 (N=1061)
	Public insurance	171 (96.1)	379 (92.7)	349 (95.6)	393 (98.3)	1292 (95.6)	899 (94.4)
	Private (insurance)	-	6 (1.5)	6 (1.6)	4 (1.0)	16 (1.2)	12 (1.3)
	Private (out of pocket)	7 (3.9)	22 (5.4)	7 (1.9)	3 (0.8)	39 (2.9)	36 (3.8)
	Combination	-	2 (0.5)	3 (0.8)	-	5 (0.4)	5 (0.5)
	Unknown	12	47	50	33	142	109
Treatment Sector, n(%)	n (missing)	183 (0)	422 (0)	394 (0)	413 (0)	1412 (0)	999 (0)
	In the public sector	155 (84.7)	393 (93.1)	354 (89.8)	386 (93.5)	1288 (91.2)	902 (90.3)
	In the private sector	28 (15.3)	29 (6.9)	40 (10.2)	27 (6.5)	124 (8.8)	97 (9.7)
	Unknown	7	34	21	20	82	62



**Table 05 : Vital signs and life style  
Full Analysis Dataset : THAILAND**

Variable	Statistics	Cohort 2 (N=190) (n %)	Cohort 3 (N=456) (n %)	Cohort 4 (N=415) (n %)	Cohort 5 (N=433) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1494)	Total Prospective patients Cohorts 1 to 4 (N=1061)
Height (cm)	n (missing)	149 (41)	324 (132)	285 (130)	343 (90)	1101 (393)	758 (303)
	Mean (SD)	159.6 (9.4)	160.4 (8.9)	161.9 (8.9)	161.6 (9.1)	161.0 (9.1)	160.8 (9.0)
	Median (IQR)	160.0 (151.0 to 165.0)	160.0 (154.0 to 167.0)	160.0 (155.0 to 169.0)	161.0 (156.0 to 168.0)	160.0 (155.0 to 168.0)	160.0 (154.0 to 168.0)
	Min to Max	130 to 182	140 to 190	142 to 190	130 to 185	130 to 190	130 to 190
Weight (kg)	n (missing)	149 (41)	324 (132)	285 (130)	343 (90)	1101 (393)	758 (303)
	Mean (SD)	63.4 (13.8)	64.6 (13.7)	65.9 (13.6)	64.9 (14.6)	64.9 (14.0)	64.8 (13.7)
	Median (IQR)	64.0 (53.0 to 70.0)	64.0 (55.0 to 72.5)	65.0 (57.0 to 72.0)	64.0 (55.0 to 72.0)	64.0 (56.0 to 72.0)	64.0 (56.0 to 72.0)
	Min to Max	31 to 103	32 to 130	35 to 110	31 to 125	31 to 130	31 to 130
BMI (kg/m <sup>2</sup> )	n (missing)	149 (41)	324 (132)	285 (130)	343 (90)	1101 (393)	758 (303)
	Mean (SD)	24.8 (4.4)	25.0 (4.4)	25.1 (4.7)	24.8 (4.7)	25.0 (4.6)	25.0 (4.5)
	Median (IQR)	25.0 (22.0 to 27.0)	25.0 (22.0 to 28.0)	25.0 (22.0 to 27.0)	24.0 (22.0 to 27.0)	25.0 (22.0 to 27.0)	25.0 (22.0 to 27.0)
	Min to Max	15 to 39	14 to 41	15 to 49	12 to 43	12 to 49	14 to 49
BMI Category, n(%)	n (missing)	149 (41)	324 (132)	285 (130)	343 (90)	1101 (393)	758 (303)
	<19	15 (10.1)	21 (6.5)	18 (6.3)	29 (8.5)	83 (7.5)	54 (7.1)
	19-<25	60 (40.3)	149 (46.0)	133 (46.7)	168 (49.0)	510 (46.3)	342 (45.1)
	25-<30	57 (38.3)	112 (34.6)	97 (34.0)	107 (31.2)	373 (33.9)	266 (35.1)
	30-<40	17 (11.4)	39 (12.0)	34 (11.9)	36 (10.5)	126 (11.4)	90 (11.9)
	>=40	-	3 (0.9)	3 (1.1)	3 (0.9)	9 (0.8)	6 (0.8)
Pulse (bpm)	n (missing)	189 (1)	448 (8)	404 (11)	425 (8)	1466 (28)	1041 (20)
	Mean (SD)	84.5 (21.6)	88.4 (23.4)	86.2 (22.2)	84.4 (20.2)	86.2 (22.0)	86.9 (22.6)
	Median (IQR)	80.0 (68.0 to 97.0)	85.0 (70.0 to 103.5)	84.0 (70.0 to 98.0)	82.0 (70.0 to 97.0)	84.0 (70.0 to 100.0)	84.0 (70.0 to 100.0)
	Min to Max	48 to 164	45 to 166	40 to 200	38 to 155	38 to 200	40 to 200

**Table 05 : Vital signs and life style  
Full Analysis Dataset : THAILAND**

Variable	Statistics	Cohort 2 (N=190) (n %)	Cohort 3 (N=456) (n %)	Cohort 4 (N=415) (n %)	Cohort 5 (N=433) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1494)	Total Prospective patients Cohorts 1 to 4 (N=1061)
Systolic BP (mm Hg)	n (missing)	189 (1)	447 (9)	412 (3)	427 (6)	1475 (19)	1048 (13)
	Mean (SD)	130.2 (20.1)	132.0 (21.3)	132.2 (19.5)	131.8 (19.4)	131.8 (20.1)	131.8 (20.4)
	Median (IQR)	130.0 (116.0 to 145.0)	131.0 (118.0 to 143.0)	131.0 (119.0 to 145.0)	132.0 (118.0 to 145.0)	131.0 (118.0 to 144.0)	131.0 (118.0 to 144.0)
	Min to Max	80 to 177	80 to 254	92 to 204	71 to 185	71 to 254	80 to 254
Diastolic BP (mm Hg)	n (missing)	189 (1)	447 (9)	412 (3)	427 (6)	1475 (19)	1048 (13)
	Mean (SD)	77.8 (12.5)	78.3 (14.7)	76.8 (14.2)	77.1 (13.8)	77.5 (14.0)	77.6 (14.1)
	Median (IQR)	78.0 (69.0 to 86.0)	77.0 (69.0 to 88.0)	75.5 (67.0 to 87.0)	76.0 (68.0 to 87.0)	77.0 (68.0 to 87.0)	77.0 (68.0 to 87.0)
	Min to Max	49 to 118	44 to 141	37 to 140	41 to 137	37 to 141	37 to 141
LVEF (%)	n (missing)	139 (51)	311 (145)	325 (90)	317 (116)	1092 (402)	775 (286)
	Mean (SD)	61.2 (13.1)	61.4 (13.9)	61.0 (13.5)	60.7 (13.7)	61.0 (13.6)	61.2 (13.6)
	Median (IQR)	63.0 (55.0 to 70.0)	63.0 (55.0 to 70.0)	64.0 (55.0 to 70.0)	63.0 (55.0 to 69.0)	64.0 (55.0 to 70.0)	64.0 (55.0 to 70.0)
	Min to Max	15 to 87	16 to 93	15 to 86	11 to 82	11 to 93	15 to 93
LVEF Category, n (n(%))	n (missing)	139 (51)	311 (145)	325 (90)	317 (116)	1092 (402)	775 (286)
	<40%	10 (7.2)	29 (9.3)	28 (8.6)	30 (9.5)	97 (8.9)	67 (8.6)
	>=40%	129 (92.8)	282 (90.7)	297 (91.4)	287 (90.5)	995 (91.1)	708 (91.4)
History of Hypertension, n(%)	n (missing)	190 (0)	453 (0)	415 (0)	433 (0)	1491 (0)	1058 (0)
	No	41 (21.6)	126 (27.8)	137 (33.0)	125 (28.9)	429 (28.8)	304 (28.7)
	Yes	149 (78.4)	327 (72.2)	278 (67.0)	308 (71.1)	1062 (71.2)	754 (71.3)

**Table 05 : Vital signs and life style  
Full Analysis Dataset : THAILAND**

Variable	Statistics	Cohort 2 (N=190) (n %)	Cohort 3 (N=456) (n %)	Cohort 4 (N=415) (n %)	Cohort 5 (N=433) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1494)	Total Prospective patients Cohorts 1 to 4 (N=1061)
	Unknown	-	3	-	-	3	3
Alcohol Consumption, n(%)	n (missing)	169 (0)	360 (0)	343 (0)	339 (0)	1211 (0)	872 (0)
	Abstinent	150 (88.8)	307 (85.3)	281 (81.9)	283 (83.5)	1021 (84.3)	738 (84.6)
	Light	12 (7.1)	31 (8.6)	40 (11.7)	31 (9.1)	114 (9.4)	83 (9.5)
	Moderate	6 (3.6)	15 (4.2)	13 (3.8)	14 (4.1)	48 (4.0)	34 (3.9)
	Heavy	1 (0.6)	7 (1.9)	9 (2.6)	11 (3.2)	28 (2.3)	17 (1.9)
	Unknown	21	96	72	94	283	189
Smoker, n(%)	n (missing)	185 (0)	409 (0)	379 (0)	374 (0)	1347 (0)	973 (0)
	No	155 (83.8)	329 (80.4)	302 (79.7)	293 (78.3)	1079 (80.1)	786 (80.8)
	Ex-smoker	23 (12.4)	55 (13.4)	55 (14.5)	62 (16.6)	195 (14.5)	133 (13.7)
	Current smoker	7 (3.8)	25 (6.1)	22 (5.8)	19 (5.1)	73 (5.4)	54 (5.5)
	Unknown	5	47	36	59	147	88

**Table 06 : Clinical History**  
**Full Analysis Dataset : THAILAND**

Variable	Statistics	Cohort 2 (N=190) (n %)	Cohort 3 (N=456) (n %)	Cohort 4 (N=415) (n %)	Cohort 5 (N=433) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1494)	Total Prospective patients Cohorts 1 to 4 (N=1061)
Congestive heart failure, n(%)	n (missing)	190 (0)	456 (0)	415 (0)	433 (0)	1494 (0)	1061 (0)
	No	162 (85.3)	366 (80.3)	342 (82.4)	364 (84.1)	1234 (82.6)	870 (82.0)
	Yes	28 (14.7)	90 (19.7)	73 (17.6)	69 (15.9)	260 (17.4)	191 (18.0)
Congestive Heart Failure NYHA Class, n(%)	n (missing)	27 (162)	80 (366)	64 (342)	60 (364)	231 (1234)	171 (870)
	I	10 (37.0)	22 (27.5)	12 (18.8)	10 (16.7)	54 (23.4)	44 (25.7)
	II	12 (44.4)	43 (53.8)	40 (62.5)	37 (61.7)	132 (57.1)	95 (55.6)
	III	5 (18.5)	9 (11.3)	10 (15.6)	12 (20.0)	36 (15.6)	24 (14.0)
	IV	-	6 (7.5)	2 (3.1)	1 (1.7)	9 (3.9)	8 (4.7)
	Unknown	1	10	9	9	29	20
Coronary artery disease, n(%)	n (missing)	190 (0)	456 (0)	415 (0)	433 (0)	1494 (0)	1061 (0)
	No	163 (85.8)	416 (91.2)	353 (85.1)	387 (89.4)	1319 (88.3)	932 (87.8)
	Yes	27 (14.2)	40 (8.8)	62 (14.9)	46 (10.6)	175 (11.7)	129 (12.2)
Acute coronary syndrome, n(%)	n (missing)	190 (0)	454 (0)	413 (0)	431 (0)	1488 (0)	1057 (0)
	No	178 (93.7)	429 (94.5)	381 (92.3)	403 (93.5)	1391 (93.5)	988 (93.5)
	Yes	12 (6.3)	25 (5.5)	32 (7.7)	28 (6.5)	97 (6.5)	69 (6.5)
	Unknown	-	2	2	2	6	4
Carotid Occlusive Disease, n(%)	n (missing)	190 (0)	454 (0)	415 (0)	428 (0)	1487 (0)	1059 (0)
	No	189 (99.5)	452 (99.6)	413 (99.5)	424 (99.1)	1478 (99.4)	1054 (99.5)

**Table 06 : Clinical History**  
**Full Analysis Dataset : THAILAND**

Variable	Statistics	Cohort 2 (N=190) (n %)	Cohort 3 (N=456) (n %)	Cohort 4 (N=415) (n %)	Cohort 5 (N=433) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1494)	Total Prospective patients Cohorts 1 to 4 (N=1061)
	Yes	1 (0.5)	2 (0.4)	2 (0.5)	4 (0.9)	9 (0.6)	5 (0.5)
	Unknown	-	2	-	5	7	2
PE or DVT, n(%)	n (missing)	190 (0)	454 (0)	414 (0)	431 (0)	1489 (0)	1058 (0)
	No	189 (99.5)	452 (99.6)	414 (100.0)	429 (99.5)	1484 (99.7)	1055 (99.7)
	Yes	1 (0.5)	2 (0.4)	-	2 (0.5)	5 (0.3)	3 (0.3)
	Unknown	-	2	1	2	5	3
Other Thromboemboli sm, n(%)	n (missing)	187 (3)	0 (456)	0 (415)	0 (433)	187 (1307)	187 (874)
	No	187 (100.0)	-	-	-	187 (100.0)	187 (100.0)
Systemic Embolization, n(%)	n (missing)	189 (0)	454 (0)	412 (0)	432 (0)	1487 (0)	1055 (0)
	No	188 (99.5)	446 (98.2)	410 (99.5)	429 (99.3)	1473 (99.1)	1044 (99.0)
	Yes	1 (0.5)	8 (1.8)	2 (0.5)	3 (0.7)	14 (0.9)	11 (1.0)
	Unknown	1	2	3	1	7	6
Coronary Artery Bypass Graft, n(%)	n (missing)	190 (0)	456 (0)	413 (0)	432 (0)	1491 (0)	1059 (0)
	No	185 (97.4)	452 (99.1)	411 (99.5)	423 (97.9)	1471 (98.7)	1048 (99.0)
	Yes	5 (2.6)	4 (0.9)	2 (0.5)	9 (2.1)	20 (1.3)	11 (1.0)
	Unknown	-	-	2	1	3	2
Stroke/TIA, n(%)	n (missing)	190 (0)	456 (0)	415 (0)	433 (0)	1494 (0)	1061 (0)
	No	163 (85.8)	419 (91.9)	377 (90.8)	383 (88.5)	1342 (89.8)	959 (90.4)

**Table 06 : Clinical History**  
**Full Analysis Dataset : THAILAND**

Variable	Statistics	Cohort 2 (N=190) (n %)	Cohort 3 (N=456) (n %)	Cohort 4 (N=415) (n %)	Cohort 5 (N=433) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1494)	Total Prospective patients Cohorts 1 to 4 (N=1061)
	Yes	27 (14.2)	37 (8.1)	38 (9.2)	50 (11.5)	152 (10.2)	102 (9.6)
Stroke, n(%)	n (missing)	190 (0)	455 (0)	413 (0)	432 (0)	1490 (0)	1058 (0)
	No	167 (87.9)	422 (92.7)	384 (93.0)	389 (90.0)	1362 (91.4)	973 (92.0)
	Yes	23 (12.1)	33 (7.3)	29 (7.0)	43 (10.0)	128 (8.6)	85 (8.0)
	Unknown	-	1	2	1	4	3
History of Bleeding, n(%)	n (missing)	190 (0)	455 (0)	414 (0)	432 (0)	1491 (0)	1059 (0)
	No	185 (97.4)	451 (99.1)	409 (98.8)	424 (98.1)	1469 (98.5)	1045 (98.7)
	Yes	5 (2.6)	4 (0.9)	5 (1.2)	8 (1.9)	22 (1.5)	14 (1.3)
	Unknown	-	1	1	1	3	2
Hypercholester olaemia, n(%)	n (missing)	190 (0)	446 (0)	396 (0)	414 (0)	1446 (0)	1032 (0)
	No	76 (40.0)	219 (49.1)	157 (39.6)	156 (37.7)	608 (42.0)	452 (43.8)
	Yes	114 (60.0)	227 (50.9)	239 (60.4)	258 (62.3)	838 (58.0)	580 (56.2)
	Unknown	-	10	19	19	48	29
Diabetes, n(%)	n (missing)	190 (0)	456 (0)	415 (0)	433 (0)	1494 (0)	1061 (0)
	No	152 (80.0)	356 (78.1)	327 (78.8)	333 (76.9)	1168 (78.2)	835 (78.7)
	Type I	-	9 (2.0)	1 (0.2)	5 (1.2)	15 (1.0)	10 (0.9)
	Type II	38 (20.0)	91 (20.0)	87 (21.0)	95 (21.9)	311 (20.8)	216 (20.4)
Diabetes, n(%)	n (missing)	190 (0)	456 (0)	415 (0)	433 (0)	1494 (0)	1061 (0)
	No	152 (80.0)	356 (78.1)	327 (78.8)	333 (76.9)	1168 (78.2)	835 (78.7)
	Yes	38 (20.0)	100 (21.9)	88 (21.2)	100 (23.1)	326 (21.8)	226 (21.3)
Cirrhosis, n(%)	n (missing)	190 (0)	446 (0)	408 (0)	410 (0)	1454 (0)	1044 (0)
	No	190 (100.0)	440 (98.7)	396 (97.1)	398 (97.1)	1424 (97.9)	1026 (98.3)
	Yes	-	6 (1.3)	12 (2.9)	12 (2.9)	30 (2.1)	18 (1.7)

**Table 06 : Clinical History**  
**Full Analysis Dataset : THAILAND**

Variable	Statistics	Cohort 2 (N=190) (n %)	Cohort 3 (N=456) (n %)	Cohort 4 (N=415) (n %)	Cohort 5 (N=433) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1494)	Total Prospective patients Cohorts 1 to 4 (N=1061)
	Unknown	-	10	7	23	40	17
Dementia, n(%)	n (missing)	190 (0)	449 (0)	412 (0)	430 (0)	1481 (0)	1051 (0)
	No	189 (99.5)	446 (99.3)	404 (98.1)	422 (98.1)	1461 (98.6)	1039 (98.9)
	Yes	1 (0.5)	3 (0.7)	8 (1.9)	8 (1.9)	20 (1.4)	12 (1.1)
	Unknown	-	7	3	3	13	10
Hyperthyroidism, n(%)	n (missing)	189 (0)	448 (0)	407 (0)	412 (0)	1456 (0)	1044 (0)
	No	186 (98.4)	428 (95.5)	397 (97.5)	388 (94.2)	1399 (96.1)	1011 (96.8)
	Yes	3 (1.6)	20 (4.5)	10 (2.5)	24 (5.8)	57 (3.9)	33 (3.2)
	Unknown	1	8	8	21	38	17
Hypothyroidism, n(%)	n (missing)	189 (0)	447 (0)	407 (0)	412 (0)	1455 (0)	1043 (0)
	No	189 (100.0)	442 (98.9)	406 (99.8)	408 (99.0)	1445 (99.3)	1037 (99.4)
	Yes	-	5 (1.1)	1 (0.2)	4 (1.0)	10 (0.7)	6 (0.6)
	Unknown	1	9	8	21	39	18
Vascular Disease, n(%)	n (missing)	190 (0)	455 (1)	413 (2)	430 (3)	1488 (6)	1058 (3)
	No	176 (92.6)	413 (90.8)	368 (89.1)	399 (92.8)	1356 (91.1)	957 (90.5)
	Yes	14 (7.4)	42 (9.2)	45 (10.9)	31 (7.2)	132 (8.9)	101 (9.5)
Moderate to Severe CKD, n(%)	n (missing)	190 (0)	456 (0)	415 (0)	433 (0)	1494 (0)	1061 (0)
	No	145 (76.3)	390 (85.5)	341 (82.2)	346 (79.9)	1222 (81.8)	876 (82.6)
	Yes	45 (23.7)	66 (14.5)	74 (17.8)	87 (20.1)	272 (18.2)	185 (17.4)

**Table 07 : Treatment for stroke prophylaxis  
Full Analysis Dataset : THAILAND**

Variable	Statistics	Cohort 2 (N=190) (n %)	Cohort 3 (N=456) (n %)	Cohort 4 (N=415) (n %)	Cohort 5 (N=433) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1494)	Total Prospective patients Cohorts 1 to 4 (N=1061)
Baseline Treatment, n(%)	n (missing)	190 (0)	453 (0)	415 (0)	433 (0)	1491 (0)	1058 (0)
	VKA	77 (40.5)	203 (44.8)	164 (39.5)	166 (38.3)	610 (40.9)	444 (42.0)
	VKA+AP	20 (10.5)	42 (9.3)	47 (11.3)	47 (10.9)	156 (10.5)	109 (10.3)
	FXA	-	7 (1.5)	5 (1.2)	14 (3.2)	26 (1.7)	12 (1.1)
	FXA+AP	1 (0.5)	-	-	2 (0.5)	3 (0.2)	1 (0.1)
	DTI	1 (0.5)	2 (0.4)	1 (0.2)	5 (1.2)	9 (0.6)	4 (0.4)
	DTI+AP	1 (0.5)	-	1 (0.2)	2 (0.5)	4 (0.3)	2 (0.2)
	AP	70 (36.8)	122 (26.9)	123 (29.6)	125 (28.9)	440 (29.5)	315 (29.8)
	NONE	20 (10.5)	77 (17.0)	74 (17.8)	72 (16.6)	243 (16.3)	171 (16.2)
	Unknown	-	3	-	-	3	3
	VKA±AP	97 (51.1)	245 (54.1)	211 (50.8)	213 (49.2)	766 (51.4)	553 (52.3)
	FXA±AP	1 (0.5)	7 (1.5)	5 (1.2)	16 (3.7)	29 (1.9)	13 (1.2)
	DTI±AP	2 (1.1)	2 (0.4)	2 (0.5)	7 (1.6)	13 (0.9)	6 (0.6)
	FXA/DTI	1 (0.5)	9 (2.0)	6 (1.4)	19 (4.4)	35 (2.3)	16 (1.5)
	FXA/DTI+AP	2 (1.1)	-	1 (0.2)	4 (0.9)	7 (0.5)	3 (0.3)
	FXA/DTI±AP	3 (1.6)	9 (2.0)	7 (1.7)	23 (5.3)	42 (2.8)	19 (1.8)
	AC	78 (41.1)	212 (46.8)	170 (41.0)	185 (42.7)	645 (43.3)	460 (43.5)
	AC+AP	22 (11.6)	42 (9.3)	48 (11.6)	51 (11.8)	163 (10.9)	112 (10.6)
	AC±AP	100 (52.6)	254 (56.1)	218 (52.5)	236 (54.5)	808 (54.2)	572 (54.1)



**Table 08: Treatment**  
**Full Analysis Dataset : THAILAND**

	<b>Cohort 2 (N=190) (n %)</b>	<b>Cohort 3 (N=456) (n %)</b>	<b>Cohort 4 (N=415) (n %)</b>	<b>Cohort 5 (N=433) (n %)</b>	<b>Total Prospective patients Cohorts 1 to 5 (N=1494)</b>	<b>Total Prospective patients Cohorts 1 to 4 (N=1061)</b>
<b>Anti-platelet (non mutually exclusive groups)</b>						
Glycoprotein inhibitors	1 (0.5)	-	-		1 (0.1)	1 (0.1)
ADP receptor/P2Y12 inhibitors	9 (4.7)	23 (5.0)	31 (7.5)	30 (6.9)	93 (6.2)	63 (5.9)
Cox inhibitors	-	3 (0.7)	2 (0.5)		5 (0.3)	5 (0.5)
ASA	86 (45.3)	154 (33.8)	161 (38.8)	165 (38.1)	566 (37.9)	401 (37.8)
<b>Anticoagulant drugs (non mutually exclusive groups)</b>						
VKA	97 (51.1)	245 (53.7)	211 (50.8)	213 (49.2)	766 (51.3)	553 (52.1)
FXa	1 (0.5)	8 (1.8)	5 (1.2)	16 (3.7)	30 (2.0)	14 (1.3)
DTI	2 (1.1)	3 (0.7)	2 (0.5)	7 (1.6)	14 (0.9)	7 (0.7)
Heparinoid	-	-	1 (0.2)		1 (0.1)	1 (0.1)
Heparins	9 (4.7)	9 (2.0)	4 (1.0)	3 (0.7)	25 (1.7)	22 (2.1)
Other	-	-	4 (1.0)		4 (0.3)	4 (0.4)

**Table 09 : Risk scores**  
**Full Analysis Dataset : THAILAND**

Variable	Statistics	Cohort 2 (N=190) (n %)	Cohort 3 (N=456) (n %)	Cohort 4 (N=415) (n %)	Cohort 5 (N=433) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1494)	Total Prospective patients Cohorts 1 to 4 (N=1061)
CHADS2 Score	n (missing)	189 (1)	447 (9)	412 (3)	430 (3)	1478 (16)	1048 (13)
	Mean (SD)	1.8 (1.2)	1.6 (1.0)	1.6 (1.1)	1.7 (1.1)	1.7 (1.1)	1.6 (1.1)
	Median (IQR)	2.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)
	Min to Max	0 to 6	0 to 6	0 to 5	0 to 5	0 to 6	0 to 6
CHADS2 score categories, n(%)	n (missing)	189 (1)	447 (9)	412 (3)	430 (3)	1478 (16)	1048 (13)
	0	18 (9.5)	47 (10.5)	56 (13.6)	61 (14.2)	182 (12.3)	121 (11.5)
	1	70 (37.0)	179 (40.0)	151 (36.7)	146 (34.0)	546 (36.9)	400 (38.2)
	2	55 (29.1)	141 (31.5)	133 (32.3)	125 (29.1)	454 (30.7)	329 (31.4)
	3	29 (15.3)	61 (13.6)	49 (11.9)	67 (15.6)	206 (13.9)	139 (13.3)
	4	14 (7.4)	16 (3.6)	19 (4.6)	26 (6.0)	75 (5.1)	49 (4.7)
	5	2 (1.1)	2 (0.4)	4 (1.0)	5 (1.2)	13 (0.9)	8 (0.8)
	6	1 (0.5)	1 (0.2)	-	-	2 (0.1)	2 (0.2)
CHA2DS2- VASc Score	n (missing)	188 (2)	446 (10)	410 (5)	427 (6)	1471 (23)	1044 (17)
	Mean (SD)	3.1 (1.5)	2.9 (1.4)	2.8 (1.5)	2.9 (1.6)	2.9 (1.5)	2.9 (1.5)
	Median (IQR)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)
	Min to Max	0 to 7	0 to 9	0 to 7	0 to 7	0 to 9	0 to 9
CHA2DS2- VASc score categories, n(%)	n (missing)	188 (2)	446 (10)	410 (5)	427 (6)	1471 (23)	1044 (17)
	0	7 (3.7)	10 (2.2)	16 (3.9)	25 (5.9)	58 (3.9)	33 (3.2)
	1	25 (13.3)	68 (15.2)	64 (15.6)	65 (15.2)	222 (15.1)	157 (15.0)
	2	38 (20.2)	109 (24.4)	104 (25.4)	92 (21.5)	343 (23.3)	251 (24.0)
	3	42 (22.3)	121 (27.1)	102 (24.9)	99 (23.2)	364 (24.7)	265 (25.4)
	4	48 (25.5)	84 (18.8)	76 (18.5)	81 (19.0)	289 (19.6)	208 (19.9)

**Table 09 : Risk scores**  
**Full Analysis Dataset : THAILAND**

Variable	Statistics	Cohort 2 (N=190) (n %)	Cohort 3 (N=456) (n %)	Cohort 4 (N=415) (n %)	Cohort 5 (N=433) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1494)	Total Prospective patients Cohorts 1 to 4 (N=1061)
	5	15 (8.0)	39 (8.7)	31 (7.6)	43 (10.1)	128 (8.7)	85 (8.1)
	6-9	13 (6.9)	15 (3.4)	17 (4.1)	22 (5.2)	67 (4.6)	45 (4.3)
HAS-BLED score	n (missing)	128 (62)	324 (132)	314 (101)	321 (112)	1087 (407)	766 (295)
	Mean (SD)	1.7 (1.1)	1.3 (1.0)	1.5 (1.0)	1.5 (1.1)	1.5 (1.0)	1.4 (1.0)
	Median (IQR)	2.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)
	Min to Max	0 to 4	0 to 4	0 to 4	0 to 5	0 to 5	0 to 4
HAS-BLED score categories, n(%)	n (missing)	128 (62)	324 (132)	314 (101)	321 (112)	1087 (407)	766 (295)
	0	15 (11.7)	61 (18.8)	54 (17.2)	57 (17.8)	187 (17.2)	130 (17.0)
	1	46 (35.9)	147 (45.4)	109 (34.7)	120 (37.4)	422 (38.8)	302 (39.4)
	2	40 (31.3)	79 (24.4)	107 (34.1)	88 (27.4)	314 (28.9)	226 (29.5)
	3	20 (15.6)	29 (9.0)	35 (11.1)	46 (14.3)	130 (12.0)	84 (11.0)
	4	7 (5.5)	8 (2.5)	9 (2.9)	8 (2.5)	32 (2.9)	24 (3.1)
	5	-	-	-	2 (0.6)	2 (0.2)	-

**Table 10: Treatment at baseline by CHA2DS2-VASc score  
Full Analysis Dataset : THAILAND**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Cohort 2	0	1	14.3	-	-	-	-	-	-	-	-	-	-	3	42.9	3	42.9	-
	1	6	24	-	-	-	-	1	4	-	-	-	-	13	52	5	20	-
	2	11	28.9	-	-	-	-	-	-	1	2.6	-	-	21	55.3	5	13.2	-
	3	17	40.5	8	19	-	-	-	-	-	-	-	-	15	35.7	2	4.8	-
	4	29	60.4	7	14.6	-	-	-	-	-	-	1	2.1	9	18.8	2	4.2	-
	5	5	33.3	5	33.3	-	-	-	-	-	-	-	-	5	33.3	-	-	-
	6-9	7	53.8	-	-	-	-	-	-	-	-	-	-	3	23.1	3	23.1	-
Cohort 3	0	1	10	-	-	-	-	-	-	-	-	-	-	4	40	5	50	-
	1	15	22.4	5	7.5	2	3	-	-	-	-	-	-	24	35.8	21	31.3	1
	2	53	48.6	8	7.3	1	0.9	-	-	-	-	-	-	24	22	23	21.1	-
	3	61	50.4	12	9.9	3	2.5	-	-	-	-	-	-	29	24	16	13.2	-
	4	45	53.6	8	9.5	1	1.2	-	-	-	-	-	-	21	25	9	10.7	-
	5	13	35.1	5	13.5	-	-	-	-	1	2.7	-	-	16	43.2	2	5.4	2
	6-9	9	60	3	20	-	-	-	-	1	6.7	-	-	2	13.3	-	-	-
Cohort 4	0	3	18.8	1	6.3	-	-	-	-	-	-	-	-	6	37.5	6	37.5	-
	1	20	31.3	3	4.7	-	-	-	-	-	-	-	-	22	34.4	19	29.7	-
	2	45	43.3	10	9.6	2	1.9	-	-	1	1	-	-	33	31.7	13	12.5	-
	3	43	42.2	12	11.8	1	1	-	-	-	-	-	-	29	28.4	17	16.7	-
	4	35	46.1	10	13.2	1	1.3	-	-	-	-	-	-	20	26.3	10	13.2	-
	5	12	38.7	7	22.6	1	3.2	-	-	-	-	-	-	4	12.9	7	22.6	-
	6-9	4	23.5	3	17.6	-	-	-	-	-	-	1	5.9	8	47.1	1	5.9	-
Cohort 5	0	3	12	-	-	2	8	-	-	-	-	-	-	9	36	11	44	-
	1	16	24.6	2	3.1	3	4.6	-	-	3	4.6	-	-	24	36.9	17	26.2	-
	2	39	42.4	10	10.9	2	2.2	-	-	-	-	-	-	27	29.3	14	15.2	-
	3	52	52.5	9	9.1	2	2	-	-	-	-	1	1	25	25.3	10	10.1	-
	4	27	33.3	11	13.6	2	2.5	2	2.5	1	1.2	-	-	25	30.9	13	16	-
	5	16	37.2	9	20.9	3	7	-	-	1	2.3	1	2.3	8	18.6	5	11.6	-
	6-9	10	45.5	5	22.7	-	-	-	-	-	-	-	-	5	22.7	2	9.1	-

**Table 10: Treatment at baseline by CHA2DS2-VASc score  
Full Analysis Dataset : THAILAND**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Total Prospective patients Cohorts 1 to 5	0	8	13.8	1	1.7	2	3.4	-	-	-	-	-	-	22	37.9	25	43.1	-
	1	57	25.8	10	4.5	5	2.3	1	0.5	3	1.4	-	-	83	37.6	62	28.1	1
	2	148	43.1	28	8.2	5	1.5	-	-	2	0.6	-	-	105	30.6	55	16	-
	3	173	47.5	41	11.3	6	1.6	-	-	-	-	1	0.3	98	26.9	45	12.4	-
	4	136	47.1	36	12.5	4	1.4	2	0.7	1	0.3	1	0.3	75	26	34	11.8	-
	5	46	36.5	26	20.6	4	3.2	-	-	2	1.6	1	0.8	33	26.2	14	11.1	2
	6-9	30	44.8	11	16.4	-	-	-	-	1	1.5	1	1.5	18	26.9	6	9	-
Total Prospective patients Cohorts 1 to 4	0	5	15.2	1	3	-	-	-	-	-	-	-	-	13	39.4	14	42.4	-
	1	41	26.3	8	5.1	2	1.3	1	0.6	-	-	-	-	59	37.8	45	28.8	1
	2	109	43.4	18	7.2	3	1.2	-	-	2	0.8	-	-	78	31.1	41	16.3	-
	3	121	45.7	32	12.1	4	1.5	-	-	-	-	-	-	73	27.5	35	13.2	-
	4	109	52.4	25	12	2	1	-	-	-	-	1	0.5	50	24	21	10.1	-
	5	30	36.1	17	20.5	1	1.2	-	-	1	1.2	-	-	25	30.1	9	10.8	2
	6-9	20	44.4	6	13.3	-	-	-	-	1	2.2	1	2.2	13	28.9	4	8.9	-

**Table 11: Treatment at baseline by HAS-BLED score  
Full Analysis Dataset : THAILAND**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	
Cohort 2	0	8	53.3	-	-	-	-	-	-	-	-	-	-	-	-	-	7	46.7	-
	1	18	39.1	1	2.2	-	-	-	-	-	-	-	-	25	54.3	2	4.3	-	
	2	13	32.5	8	20	-	-	-	-	-	-	1	2.5	15	37.5	3	7.5	-	
	3	5	25	2	10	-	-	-	-	-	-	-	-	11	55	2	10	-	
	4-9	1	14.3	1	14.3	-	-	-	-	-	-	-	-	5	71.4	-	-	-	
Cohort 3	0	37	61.7	-	-	2	3.3	-	-	-	-	-	-	-	-	21	35	1	
	1	72	49.3	14	9.6	2	1.4	-	-	-	-	-	-	33	22.6	25	17.1	1	
	2	27	34.6	9	11.5	1	1.3	-	-	1	1.3	-	-	34	43.6	6	7.7	1	
	3	6	20.7	5	17.2	-	-	-	-	-	-	-	-	15	51.7	3	10.3	-	
	4-9	1	12.5	2	25	-	-	-	-	-	-	-	-	4	50	1	12.5	-	
Cohort 4	0	34	63	-	-	1	1.9	-	-	-	-	-	-	-	-	19	35.2	-	
	1	56	51.4	6	5.5	2	1.8	-	-	-	-	-	-	28	25.7	17	15.6	-	
	2	20	18.7	25	23.4	2	1.9	-	-	-	-	-	-	46	43	14	13.1	-	
	3	2	5.7	6	17.1	-	-	-	-	-	-	1	2.9	18	51.4	8	22.9	-	
	4-9	1	11.1	2	22.2	-	-	-	-	-	-	-	-	5	55.6	1	11.1	-	
Cohort 5	0	29	50.9	-	-	5	8.8	-	-	2	3.5	-	-	-	-	21	36.8	-	
	1	59	49.2	7	5.8	4	3.3	1	0.8	-	-	-	-	34	28.3	15	12.5	-	
	2	25	28.4	13	14.8	1	1.1	-	-	1	1.1	1	1.1	34	38.6	13	14.8	-	
	3	4	8.7	12	26.1	-	-	1	2.2	-	-	-	-	22	47.8	7	15.2	-	
	4-9	1	10	4	40	-	-	-	-	-	-	-	-	5	50	-	-	-	
Total Prospective patients Cohorts 1 to 5	0	108	58.1	-	-	8	4.3	-	-	2	1.1	-	-	-	-	68	36.6	1	
	1	205	48.7	28	6.7	8	1.9	1	0.2	-	-	-	-	120	28.5	59	14	1	
	2	85	27.2	55	17.6	4	1.3	-	-	2	0.6	2	0.6	129	41.2	36	11.5	1	
	3	17	13.1	25	19.2	-	-	1	0.8	-	-	1	0.8	66	50.8	20	15.4	-	

**Table 11: Treatment at baseline by HAS-BLED score  
Full Analysis Dataset : THAILAND**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n		
	4-9	4	11.8	9	26.5	-	-	-	-	-	-	-	-	19	55.9	2	5.9	-
Total Prospective patients Cohorts 1 to 4	0	79	61.2	-	-	3	2.3	-	-	-	-	-	-	-	-	47	36.4	1
	1	146	48.5	21	7	4	1.3	-	-	-	-	-	-	86	28.6	44	14.6	1
	2	60	26.7	42	18.7	3	1.3	-	-	1	0.4	1	0.4	95	42.2	23	10.2	1
	3	13	15.5	13	15.5	-	-	-	-	-	-	1	1.2	44	52.4	13	15.5	-
	4-9	3	12.5	5	20.8	-	-	-	-	-	-	-	-	14	58.3	2	8.3	-

**Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : THAILAND**

Variable	Statistics	Cohort 2 (N=97) (n %)	Cohort 3 (N=245) (n %)	Cohort 4 (N=211) (n %)	Total Prospective patients Cohorts 1 to 4 (N=553)
TTR value, n(%)	n (missing)	48 (49)	131 (114)	107 (104)	286 (267)
	<65	41 (85.4)	102 (77.9)	81 (75.7)	224 (78.3)
	>=65	7 (14.6)	29 (22.1)	26 (24.3)	62 (21.7)
TTR	n (missing)	48 (49)	131 (114)	107 (104)	286 (267)
	Mean (SD)	29.5 (31.9)	40.5 (28.7)	40.4 (28.7)	38.6 (29.4)
	Median (IQR)	19.2 (0.0 to 47.5)	37.5 (17.6 to 63.0)	39.5 (12.1 to 64.1)	35.9 (12.1 to 61.4)
	Min to Max	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0
INR value, n(%)	n	277	978	758	2013
	2-3	83 (30.0)	325 (33.2)	250 (33.0)	658 (32.7)
	<2	153 (55.2)	528 (54.0)	404 (53.3)	1085 (53.9)
	>3	41 (14.8)	125 (12.8)	104 (13.7)	270 (13.4)
INR	n	277	978	758	2013
	Mean (SD)	2.2 (1.5)	2.1 (1.2)	2.1 (1.1)	2.1 (1.2)
	Median (IQR)	1.9 (1.4 to 2.5)	1.9 (1.4 to 2.5)	2.0 (1.4 to 2.6)	1.9 (1.4 to 2.5)
	Min to Max	0.9 to 12.2	0.9 to 12.5	0.8 to 12.2	0.8 to 12.5



**Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : THAILAND**

Outcome	Cause	N	Events	Event rate /100 person-years	95% CI
All-cause death		1061	37	3.66	(2.65 to 5.05)
	<b>Cardiovascular death</b>	1061	1	0.10	(0.01 to 0.70)
	<b>Non-Cardiovascular death</b>	1061	27	2.67	(1.83 to 3.89)
	<b>Undetermined cause</b>	1061	9	0.89	(0.46 to 1.71)
Stroke/SE		1061	8	0.79	(0.40 to 1.59)
Major bleed		1061	11	1.09	(0.61 to 1.97)
Acute coronary syndrome		1061	2	0.20	(0.05 to 0.79)
Congestive Heart Failure		1061	8	0.79	(0.40 to 1.58)

**Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : THAILAND**

		THAILAND		
Outcome	Cause	N	Events	%
<b>Cardiovascular causes</b>	Congestive heart failure	1	1	100.00
<b>Non-cardiovascular causes</b>	Accidental / trauma	27	1	3.70
	Respiratory failure	27	2	7.41
	Infection/sepsis	27	9	33.33
	Malignancy	27	5	18.52
	Other	27	10	37.04

**Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset :THAILAND**

OUTCOME	THAILAND		
	N	Events	%
Stroke(not including systemic embolism)	1061	8	0.75
Primary Ischemic Stroke	1061	5	0.47
<i>of which secondary hemorrhagic ischemic</i>	1061	1	0.09
<b>Primary intracerebral hemorrhage*</b>	1061	2	0.19
<i>Intracerebral</i>	1061	1	0.09
<i>Subarachnoid</i>	1061	1	0.09
Undetermined	1061	1	0.09

\*Note :Multiple choice question type that allows the respondent to choose one or multiple options from the list of possible answers.

**Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : THAILAND**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	33	31.40	2	6.37	(1.59 to 25.47)
1	157	151.35	2	1.32	(0.33 to 5.28)
2	251	239.97	7	2.92	(1.39 to 6.12)
3	265	254.86	7	2.75	(1.31 to 5.76)
4+	338	319.00	18	5.64	(3.56 to 8.96)
Unknown	17	14.74	1	6.79	(0.96 to 48.17)

**Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : THAILAND**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	33	31.40	0	-	-
1	157	151.35	0	-	-
2	251	239.34	2	0.84	(0.21 to 3.34)
3	265	253.91	3	1.18	(0.38 to 3.66)
4+	338	316.52	3	0.95	(0.31 to 2.94)
Unknown	17	14.74	0	-	-

**Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : THAILAND**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	33	31.40	0	-	-
1	157	151.35	1	0.66	(0.09 to 4.69)
2	251	239.97	0	-	-
3	265	251.32	7	2.79	(1.33 to 5.84)
4+	338	317.42	3	0.95	(0.31 to 2.93)
Unknown	17	14.74	0	-	-